Biobank for interstitial lung diseases
University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank
This study is setting up a collection of health information and samples from patients with interstitial lung diseases to help researchers learn more about the condition and find better treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Kansas Medical Center Academic / other |
| Locations | 1 site (Kansas City, Kansas) |
| Trial ID | NCT05392881 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a registry and biorepository for patients with interstitial lung diseases (ILD) at the University of Kansas Medical Center. By collecting data and biological samples from patients, the researchers hope to enhance understanding of ILD, identify genetic and environmental risk factors, and discover potential treatment targets. The study will leverage the clinic's extensive patient base to facilitate research into early diagnosis and management of these conditions.
Who should consider this trial
Good fit: Ideal candidates are patients aged 18 and older who are being treated for autoimmune diseases or interstitial lung diseases at the University of Kansas Medical Center.
Not a fit: Patients who do not have interstitial lung diseases or related conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnosis and treatment options for patients with interstitial lung diseases.
How similar studies have performed: While the approach of creating a biobank for ILD is not novel, it builds on previous successful initiatives aimed at understanding rare lung diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP) 2. The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS. 3. The participant is ≥ 18 years of age. 4. The participant has signed an approved consent for this study (living patients only)
Where this trial is running
Kansas City, Kansas
- The University of Kansas Medical Center — Kansas City, Kansas, United States (Recruiting)
Study contacts
- Principal investigator: Scott Matson, M.D. — University of Kansas Medical Center
- Study coordinator: Kimberly Donnelly, Ph.D.
- Email: kdonnelly@kumc.edu
- Phone: 913-588-6067
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.